Year |
Citation |
Score |
2018 |
Schafer C, Dambrauskas N, Steel RW, Carbonetti S, Chuenchob V, Flannery EL, Vigdorovich V, Oliver BG, Roobsoong W, Maher SP, Kyle D, Sattabongkot J, Kappe SHI, Mikolajczak SA, Sather DN. A recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from dormant liver stages. Malaria Journal. 17: 370. PMID 30333026 DOI: 10.1186/S12936-018-2519-7 |
0.357 |
|
2016 |
Pearce C, Darveaux B, Rice C, Colon B, Mettel K, Rasanen K, Kyle D, Baker B, Oberlies N. The discovery and evaluation of anti-parasitic metabolites from filamentous fungi. Planta Medica. 81: S1-S381. PMID 27975882 DOI: 10.1055/S-0036-1596681 |
0.31 |
|
2016 |
Obaldía Iii N, Dow GS, Gerena L, Kyle D, Otero W, Mantel PY, Baro N, Daniels R, Mukherjee A, Childs LM, Buckee C, Duraisingh MT, Volkman SK, Wirth DF, Marti M. Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model. Scientific Reports. 6: 21216. PMID 26880111 DOI: 10.1038/Srep21216 |
0.407 |
|
2015 |
Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, ... ... Kyle DE, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 522: 315-20. PMID 26085270 DOI: 10.1038/Nature14451 |
0.301 |
|
2014 |
Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, ... ... Kyle DE, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proceedings of the National Academy of Sciences of the United States of America. 111: E5455-62. PMID 25453091 DOI: 10.1073/Pnas.1414221111 |
0.319 |
|
2014 |
Henrich PP, O'Brien C, Sáenz FE, Cremers S, Kyle DE, Fidock DA. Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model. Antimicrobial Agents and Chemotherapy. 58: 183-95. PMID 24145526 DOI: 10.1128/Aac.01466-13 |
0.317 |
|
2014 |
Siegel S, Rivero A, Kyle D. Molecular basis of extreme resistance in Plasmodium falciparum to atovaquone and other mitochondrial inhibitors Malaria Journal. 13: 81. DOI: 10.1186/1475-2875-13-S1-P81 |
0.361 |
|
2014 |
Hott A, Casandra D, Sparks K, Castarnes G, Rutter A, Kyle D. Novel phenotypic resistance to artemisinin results in reduced exposure to drug at the most sensitive stage of intraerythrocytic development in Plasmodium falciparum Malaria Journal. 13: 43. DOI: 10.1186/1475-2875-13-S1-P43 |
0.41 |
|
2013 |
Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, ... ... Kyle DE, et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Science Translational Medicine. 5: 177ra37. PMID 23515079 DOI: 10.1126/Scitranslmed.3005029 |
0.313 |
|
2012 |
Cheng Q, Kyle DE, Gatton ML. Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy? International Journal For Parasitology. Drugs and Drug Resistance. 2: 249-255. PMID 23420506 DOI: 10.1016/j.ijpddr.2012.01.001 |
0.312 |
|
2012 |
Sáenz FE, Mutka T, Udenze K, Oduola AM, Kyle DE. Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro. Antimicrobial Agents and Chemotherapy. 56: 4685-92. PMID 22710117 DOI: 10.1128/Aac.01061-12 |
0.328 |
|
2011 |
LaCrue AN, Scheel M, Kennedy K, Kumar N, Kyle DE. Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model Plasmodium vinckei. Plos One. 6: e26689. PMID 22039533 DOI: 10.1371/Journal.Pone.0026689 |
0.31 |
|
2011 |
Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malaria Journal. 10: 212. PMID 21801400 DOI: 10.1186/1475-2875-10-212 |
0.341 |
|
2009 |
Obaldía N, Milhous W, Kyle D. Adaptation of a Thai multidrug-resistant C2A clone of Plasmodium falciparum to Aotus monkeys and its preliminary in vivo antimalarial drug efficacy-resistance profile. The American Journal of Tropical Medicine and Hygiene. 81: 587-94. PMID 19815871 DOI: 10.4269/Ajtmh.2009.08-0445 |
0.337 |
|
2007 |
Xie L, Li Q, Johnson J, Zhang J, Milhous W, Kyle D. Development and validation of flow cytometric measurement for parasitaemia using autofluorescence and YOYO-1 in rodent malaria. Parasitology. 134: 1151-62. PMID 17445324 DOI: 10.1017/S0031182007002661 |
0.336 |
|
2001 |
Suswam E, Kyle D, Lang-Unnasch N. Plasmodium falciparum: the effects of atovaquone resistance on respiration. Experimental Parasitology. 98: 180-187. PMID 11560411 DOI: 10.1006/Expr.2001.4639 |
0.346 |
|
1997 |
Obaldia N, Rossan RN, Cooper RD, Kyle DE, Nuzum EO, Rieckmann KH, Shanks GD. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys American Journal of Tropical Medicine and Hygiene. 56: 508-510. PMID 9180599 DOI: 10.4269/Ajtmh.1997.56.508 |
0.326 |
|
1994 |
Gopinath R, Wongsrichanalai C, Cordón-Rosales C, Mirabelli L, Kyle D, Kain KC. Failure to detect a Plasmodium vivax-like malaria parasite in globally collected blood samples. The Journal of Infectious Diseases. 170: 1630-3. PMID 7996011 DOI: 10.1093/Infdis/170.6.1630 |
0.317 |
|
1992 |
Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Suntharasamai P, Charoenlarp P, Arnold K, Kyle D, Canfield C, Webster K. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet. 339: 821-4. PMID 1347854 DOI: 10.1016/0140-6736(92)90276-9 |
0.337 |
|
1992 |
Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle D, Webster K. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. The Lancet. 339: 369-369. PMID 1346445 DOI: 10.1016/0140-6736(92)91690-A |
0.325 |
|
Show low-probability matches. |